Christophe Pouchoy, Managing Director and Managing Director of Trecento Asset Management, co-manager of the Trecento Santé fund, commented on the derogation of homeopathy envisaged by the High Authority of Health in the columns of Challenges magazine. “Consumers are not going to be totally diverted from these products which, if they are ultimately considered ineffective, are…
Christophe Pouchoy, Managing Director and Chief Investment Officer of Trecento Asset Management, co-manager of the Trecento Santé fund, answered Challenges magazine’s questions about big pharmas’ appetite for the oncology market and its growth prospects, as evidenced by recent acquisitions (Celgene, Loxo Oncology …) for several billions of dollars. Christophe Pouchoy traced the evolutions of the…
The managers of the Trecento Santé fund, Alice Lhabouz and Christophe Pouchoy, explain in AF2i’s quarterly letter why the healthcare sector is an attractive stock market theme. “These catalysts enable the health sector to grow by 5% to 6% a year on average, when global economic growth is barely exceeding 3.5%.” In the short and…
“Our approach is different: the Trecento health fund has been the least volatile of the market since its creation (…) The health sector has proved its ability to withstand difficult times, but in this context in this market, it is better to choose the least risky fund “, comments Alice Lhabouz, President and Founder of…
While the High Authority for Health (HAS) should give an opinion on the merits of the reimbursement of homeopathic medicines in June, industry players launched Wednesday a campaign to defend homeopathy. For Christophe Pouchoy, co-manager of the Trecento Santé fund, a possible derogation would not put an industry in good health on the ground today.…
Christophe Pouchoy, Managing Director and Managing Director of Trecento Asset Management, co-manager of the Trecento Santé fund, commented on the transformation of Novartis and in particular its business model in Challenges magazine. “Vas Narasimhan understood that it was necessary to accelerate the transformation, and too bad if it (…)” Read the article by clicking here…
Christophe Pouchoy, Managing Director and Managing Director of Trecento Asset Management, co-manager of the Trecento Santé fund, answered questions from the Pharmaceutiques magazine about the recent acquisitions and some reconciliations of big pharma and major biotech companies. “Because, before buying a company, the laboratories study the expected sales multiples over the coming years and the…
Christophe Pouchoy, Managing Director and Managing Director of Trecento Asset Management, analyzed the boom in homeopathy in the Challenges magazine. “With 24% of turnover in 2017 for promotional expenses – and less than 1% for research expenses – Boiron has the (…)” Read the article by clicking here (available in French only)
To answer institutional investors’ demand regarding the fund Trecento Santé, we have decided at the end of December to create a new share class in euros, called “I EUR” (ISIN : FR0013392461). This share class was first subscribed on 31st December 2018. With a minimum investment of EUR 3 millions, this share class I EUR…
Alice Lhabouz, CEO and Founder of Trecento AM, explains why the valuation of the new group is high, and advises to wait until 2019 to have a clear vision of the strategy of the new group. “In a fragmented low-growth market, the merger with Luxottica makes sense in the long term. The synergies announced seem…
